CT-868 for Obesity

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Obesity+4 More
CT-868 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug to see if it can lower HbA1c in overweight and obese people with type 2 diabetes.

Eligible Conditions
  • Obesity
  • Type2 Diabetes

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline up to 12 and 26 weeks

Week 26
Change in hemoglobin A1c (HbA1c)
Change in mean body weight
Fasting plasma glucose

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

CT-868 Low Dose
1 of 3
CT-868 Maximum Tolerated Dose
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

96 Total Participants · 3 Treatment Groups

Primary Treatment: CT-868 · Has Placebo Group · Phase 2

CT-868 Low Dose
Drug
Experimental Group · 1 Intervention: CT-868 · Intervention Types: Drug
CT-868 Maximum Tolerated Dose
Drug
Experimental Group · 1 Intervention: CT-868 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline up to 12 and 26 weeks

Who is running the clinical trial?

Carmot Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
128 Total Patients Enrolled
Michael ElliottStudy DirectorCarmot Therapeutics, Inc.
2 Previous Clinical Trials
128 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
People who have type 2 diabetes are either male or female.
A BMI of 27 kg/m2 or more is considered obese.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.